Market Signal Briefing

NEW YORK, Nov. 11, 2025 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Molina Healthcare, Inc. (NYSE: MOH) between February 5, 2025 and July 23, 2025, both dates inclusive (the “Class Period”), of the important December 2, 2025 lead plaintiff deadline.

SO WHAT: If you purchased Molina securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Molina class action, go to https://rosenlegal.com/submit-form/?case_id=45913 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than December 2, 2025. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, defendants throughout the Class Period failed to disclose to investors: (1) material, adverse facts concerning Molina’s “medical cost trend assumptions;” (2) that Molina was experiencing a “dislocation between premium rates and medical cost trend;” (3) that Molina’s near term growth was dependent on a lack of “utilization of behavioral health, pharmacy, and inpatient and outpatient services;” (4) as a result of the foregoing, Molina’s financial guidance for fiscal year 2025 was substantially likely to be cut; and (5) as a result of the foregoing, defendants’ positive statements about Molina’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Molina class action, go to https://rosenlegal.com/submit-form/?case_id=45913 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

        Laurence Rosen, Esq.
        Phillip Kim, Esq.
        The Rosen Law Firm, P.A.
        275 Madison Avenue, 40th Floor
        New York, NY 10016
        Tel: (212) 686-1060
        Toll Free: (866) 767-3653
        Fax: (212) 202-3827
        [email protected]
        www.rosenlegal.com

Visa Inc (NYSE:V, ETR:3V64) and Mastercard Inc (NYSE:MA) have reached a proposed settlement with US merchants aimed at resolving more than two decades of litigation over credit card interchange fees and merchant rules, a deal that could reshape how retailers manage payment costs and how consumers are charged at checkout.

The agreement would reduce the average effective interchange fee merchants pay on US credit card transactions by roughly 10 basis points, or 0.1 percentage point, for five years.

The change, while modest in scale compared to typical fee levels of around 2% to 2.5%, could translate into billions of dollars in potential savings across millions of transactions.

Under the settlement, merchants would also gain greater flexibility in how they handle card payments. They could impose surcharges of up to 3% on Visa or Mastercard transactions, even if they do not apply such fees to cards from other networks.

In addition, the long-standing “honor all cards” rule, which required merchants to accept all Visa or Mastercard credit cards if they accepted any, would be relaxed. Merchants could now choose whether to accept premium or business cards within each network, though they must still treat all issuers equally within a card category.

The deal, which still requires approval from a federal judge, is expected to take effect in late 2026 or early 2027.

Analysts at USB said the proposed agreement moves Visa and Mastercard closer to resolving a major legal overhang without directly affecting their core network fees.

“This settlement follows approximately 20 years of litigation, including a prior March 2024 settlement that was rejected by the Court in June 2024, as well as monetary damages previously settled and/or expected to be settled,” they noted.  

The analysts added that Visa and Mastercard’s concessions, including surcharging flexibility and allowing merchants to form collective buying groups, are significant from a policy standpoint but limited in financial impact.

Shares of Visa added 1.2% at about $339 on the deal, while Mastercard stock was up 0.8% at $558.

$5.3 million Upfront with up to an Additional $5.8 million of Aggregate Gross Proceeds upon the Cash Exercise in Full of Warrants

November 11, 2025 15:31 ET

 | Source:

PDS Biotechnology Corporation

PRINCETON, N.J., Nov. 11, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today announced that it has entered into a securities purchase agreement for the purchase and sale of 5,800,000 shares of common stock (or pre-funded warrants in lieu thereof) at a purchase price of $0.91 per share and accompanying warrants to purchase up to an aggregate of 5,800,000 shares of its common stock in a registered direct offering (the “Offering”). The warrants will have an exercise price of $1.00 per share, will be exercisable beginning six months after issuance and will expire five years from the initial exercise date. The Offering is expected to close on or about November 12, 2025, subject to the satisfaction of customary closing conditions.

Craig-Hallum is acting as the exclusive placement agent for the offering.

The initial gross proceeds to the Company from the Offering are expected to be approximately $5.3 million, before deducting the placement agent’s fees and other offering expenses payable by the Company upon the closing of the Offering and up to an additional $5.8 million may be funded upon the full cash exercise of the warrants. The Company currently intends to use the net proceeds from the offering for the continuation of its ongoing VERSATILE-003 Phase 3 clinical trial following planned discussions with the Food and Drug Administration (FDA) regarding an amendment to the trial’s protocol, that would allow for an expedited approval pathway for PDS0101 and for other research and development expenses and general corporate purposes.

For the three month period ended September 30, 2025, the Company had approximately $26.2 million of cash and cash equivalents. This is derived from the Company’s internal books and records and is subject to the completion of financial closing procedures, final adjustments and other developments which may arise between now and the time the financial results for the quarter ended September 30, 2025 are finalized. Therefore, actual results may differ materially from this estimate, and all of the preliminary estimates are subject to change. In addition, preliminary unaudited financial information for the Company’s three month period ended September 30, 2025 is not necessarily indicative of operating results for any future period.

The Offering is being made pursuant to a “shelf” registration statement on Form S-3 (Registration No. 333-267041), including a base prospectus, previously filed with the Securities and Exchange Commission (SEC) on August 24, 2022 and declared effective by the SEC on September 2, 2022. The offering of the securities to be issued in the Offering are being made only by means of a prospectus supplement that forms a part of the registration statement. A final prospectus supplement and an accompanying base prospectus relating to the Offering will be filed with the SEC and will be available on the SEC’s website located at http://www.sec.gov. Electronic copies of the final prospectus supplement and accompanying base prospectus may also be obtained, when available, by contacting Craig-Hallum Capital Group LLC, Attention: Equity Capital Markets, 323 North Washington Ave., Minneapolis, MN 55401, by telephone at (612) 334-6300 or by email at [email protected].

The Company also has agreed to amend certain existing warrants to purchase up to an aggregate of 5,948,334 shares of the Company’s common stock that were previously issued to investors in February 2025, with an exercise price of $1.50 per share, effective upon the closing of the Offering, such that the amended warrants will have a reduced exercise price of $1.00 per share and will be exercisable beginning six months after the closing of the Offering.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

About PDS Biotechnology

PDS Biotechnology is a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers. The Company has initiated a pivotal clinical trial to advance its lead program in advanced HPV16-positive head and neck squamous cell cancers. PDS Biotech’s lead investigational targeted immunotherapy PDS0101 (Versamune® HPV) is being developed in combination with a standard-of-care immune checkpoint inhibitor, and also in a triple combination including PDS01ADC, an IL-12 fused antibody drug conjugate (ADC), and a standard-of-care immune checkpoint inhibitor. PDS01ADC is being evaluated in multiple phase 2 trials in various cancer indications in combination with standard of care.

For more information, please visit www.pdsbiotech.com

Forward Looking Statements

This communication contains forward-looking statements (including within the meaning of Section 21E of the United States Securities Exchange Act of 1934, as amended, and Section 27A of the United States Securities Act of 1933, as amended) concerning PDS Biotechnology Corporation and other matters, including, without limitation, statements regarding the consummation of the Offering, the satisfaction of closing conditions and the use of proceeds from the Offering. These statements may discuss goals, intentions and expectations as to future plans, trends, events, results of operations or financial condition, or otherwise, based on current beliefs of the Company’s management, as well as assumptions made by, and information currently available to, management. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as “may,” “will,” “should,” “would,” “expect,” “anticipate,” “plan,” “likely,” “believe,” “estimate,” “project,” “intend,” “forecast,” “guidance”, “outlook” and other similar expressions among others. Forward-looking statements are based on current beliefs and assumptions that are subject to risks and uncertainties and are not guarantees of future performance. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors, including, without limitation: the Company’s ability to protect its intellectual property rights; the Company’s anticipated capital requirements, including the Company’s anticipated cash runway and the Company’s current expectations regarding its plans for future equity financings; the Company’s dependence on additional financing to fund its operations and complete the development and commercialization of its product candidates, and the risks that raising such additional capital may restrict the Company’s operations or require the Company to relinquish rights to the Company’s technologies or product candidates; the Company’s limited operating history in the Company’s current line of business, which makes it difficult to evaluate the Company’s prospects, the Company’s business plan or the likelihood of the Company’s successful implementation of such business plan; the timing for the Company or its partners to conduct clinical trials for PDS0101 (Versamune® HPV), PDS01ADC, PDS0103 (Versamune® MUC1) and other Versamune® based product candidates; the future success of such trials; the successful implementation of the Company’s research and development programs and collaborations, including any collaboration studies concerning PDS0101 (Versamune® HPV), PDS01ADC, PDS0103 (Versamune® MUC1) and other Versamune® based product candidates and the Company’s interpretation of the results and findings of such programs and collaborations and whether such results are sufficient to support the future success of the Company’s product candidates; the success, timing and cost of the Company’s or its partners’ ongoing clinical trials and anticipated clinical trials for the Company’s current product candidates, including statements regarding response rates, the timing of initiation, pace of enrollment and completion of the trials (including the Company’s ability to fully fund its disclosed clinical trials, which assumes no material changes to the Company’s currently projected expenses), futility analyses, presentations at conferences and data reported in an abstract, and receipt of interim or preliminary results (including, without limitation, any preclinical results or data), which are not necessarily indicative of the final results of the Company’s ongoing clinical trials; any Company statements about its understanding of product candidates mechanisms of action and interpretation of preclinical and early clinical results from its clinical development programs and any collaboration studies; the Company’s ability to continue as a going concern; and other factors, including legislative, regulatory, political and economic developments not within the Company’s control. The foregoing review of important factors that could cause actual events to differ from expectations should not be construed as exhaustive and should be read in conjunction with statements that are included herein and elsewhere, including the other risks, uncertainties, and other factors described under “Risk Factors,” “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and elsewhere in the documents we file with the U.S. Securities and Exchange Commission. The forward-looking statements are made only as of the date of this press release and, except as required by applicable law, the Company undertakes no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise.

Versamune® is a registered trademark of PDS Biotechnology Corporation.

Investor Contact:

Mike Moyer
LifeSci Advisors
Phone +1 (617) 308-4306
Email: [email protected]

Media Contact:

David Schull
Russo Partners
Phone +1 (858) 717-2310
Email: [email protected]

Q3: 2025-11-10 Earnings SummaryEPS of $0.34 beats by $0.10

 |

Revenue of

$35.12M

(5.18% Y/Y)

beats by $2.22M

Consolidated Water Co. Ltd. (CWCO) Q3 2025 Earnings Call November 11, 2025 11:00 AM EST

Company Participants

Frederick McTaggart - CEO, President & Director
David Sasnett - Executive VP & CFO

Conference Call Participants

Gerard Sweeney - ROTH Capital Partners, LLC, Research Division

Presentation

Operator

Good morning. Thank you for joining us today to discuss Consolidated Water Company's third quarter 2025 operating and financial results. Hosting the call today is the Chief Executive Officer of Consolidated Water, Rick McTaggart; and the company's Chief Financial Officer, David Sasnett. Following their remarks, we'll open the call to your questions.

[Operator Instructions] Before we conclude today's call, I'll provide some important cautions regarding the forward-looking statements made by management during the call. I'd like to remind everyone that today's call is being recorded, and it will be made available for telecom replay. Please see the instructions in yesterday's press release that has been posted to the Investor Relations section of the company's website.

Now I'd like to turn the call over to Consolidated Water's CEO, Rick McTaggart. Sir, please go ahead.

Frederick McTaggart
CEO, President & Director

Thank you, Chloe, and good morning, everyone. Thank you for joining us today to discuss our financial and operating results for our third quarter of 2025.

In the third quarter, our diversified water business model, which encompasses regulated utility operations, design and construction services, O&M services, and manufacturing continued to deliver strong performance. This steady progress led to a notable increase in overall revenue and earnings per share from our continuing operations compared to the same period last year.

Retail water sales in the exclusive utility service area on Grand Cayman were higher than the previous year because of ongoing strength of the economy in the Cayman Islands and drier weather conditions on Grand Cayman. We

Recommended For You

November 11, 2025 3:33 PM EST | Source: The Rosen Law Firm PA
New York, New York--(Newsfile Corp. - November 11, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Quanex Building Products Corporation (NYSE: NX) between December 12, 2024 and September 5, 2025, both dates inclusive (the "Class Period"), of the important November 18, 2025 lead plaintiff deadline.

SO WHAT: If you purchased Quanex securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Quanex class action, go to https://rosenlegal.com/submit-form/?case_id=45157 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than November 18, 2025. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved, at the time, the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, throughout the Class Period, defendants made false and misleading statements and/or failed to disclose that: (1) Quanex's procedures and policies regarding tooling and equipment maintenance in its Tyman Mexico facility were significantly "underinvested"; (2) as a result, Quanex's tooling and equipment conditions had significantly degraded to near "catastrophic" levels; (3) as a result of the foregoing, Quanex was likely to incur significant costs, "pushing out the timing" of expected benefits from the Tyman integration; (4) Quanex had previously identified the foregoing issues; and (5) as a result of the foregoing, defendants' positive statements about Quanex's business, operations, and prospects were materially misleading and/or lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Quanex class action, go to https://rosenlegal.com/submit-form/?case_id=45157 call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

-------------------------------

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/274031

Chainlink (LINK) is facing continuous bearish pressure, struggling to break key resistance. Market analyst GainMuse notes a series of lower highs, highlighting persistent seller dominance and stalled recovery attempts.

Notably, Chainlink’s attempts to recover from the $17–$17.5 zone have repeatedly failed, turning a potential support area into a strong resistance level.

Each rebound has been met with selling pressure, keeping LINK trapped below key resistance and stalling any bullish momentum.

What does this mean? Technical patterns indicate a clear bearish bias. A series of lower highs signals weakening buyer momentum, as each rally fails to reach the prior peaks. This diminishing investor appetite often foreshadows further declines, as sellers consolidate control over the market.

Therefore, LINK’s failure to hold the $17–$17.5 recovery zone highlights the market’s heightened sensitivity, where even minor news triggers sharp moves amid prevailing bearish sentiment. The cryptocurrency now trades at $15.73.

Advertisement
 

UBS Executes World’s First Live Tokenised Fund Transaction via Chainlink DTA
UBS, managing over $6 trillion in assets, has completed the world’s first live tokenised fund transaction using Chainlink’s Digital Transfer Agent (DTA) standard, proving that complex fund operations can now run entirely on-chain under real market conditions.

UBS’s adoption of the Chainlink DTA standard marks a major leap in integrating blockchain into traditional finance. 

The tokenized system digitizes fund share issuance, transfer, and redemption, delivering instant settlement, automated compliance, and fully auditable on-chain transactions, streamlining processes that once relied on manual reconciliation and intermediaries.

The rise of tokenized funds signals a shift in bridging traditional finance with decentralized technologies. For UBS, this move goes beyond a proof of concept, it’s a strategic step to modernize fund operations, reduce risk, streamline workflows, cut costs, and enable faster, more secure cross-border transactions for institutional and private clients.

What’s unique about Chainlink’s DTA standard? Well, it bridges traditional finance and blockchain by ensuring regulatory compliance while delivering the speed, transparency, and efficiency of on-chain transactions. This enables fund managers to execute tokenized funds at scale without compromising on legal requirements, removing a key barrier to institutional adoption.

Meanwhile, on-chain analytics firm Santiment recently reported that Chainlink has strengthened its lead in DeFi development, further distancing itself from competitors.

XRP is trading at $2.42 to $2.437 over the last hour as of Nov. 11, 2025, down 5% on the day but still clinging to an 8% gain for the week. The cryptocurrency's market capitalization hovers at $145 billion, backed by a decent 24-hour trading volume of $4.45 billion.

In a recent social media post, Ethereum co-founder Vitalik Buterin has opined that in the future, when anti-aging therapies or significant lifespan/healthspan extensions exist, people will look back at our current era and be shocked that we tolerated age-related deaths as "normal." 

The prominent Canadian developer believes that aging is a preventable problem.

The billionaire often combines tech optimism, long-term thinking, and effective altruism as part of his philosophy.

HOT Stories

In early 2018, he donated roughly $2.4 million in Ether to the SENS Research Foundation, a nonprofit focused on the biomedical research of rejuvenation therapies. 

Buterin has previously described aging as "one of the greatest problems facing humanity." 

Back in 2020, the cryptocurrency luminary predicted that there would be a shift toward biotech. The "final boss": massively extending healthy life-span and ending aging entirely.

"So like basically, you know, just imagine the concept of your grandmother dying, just kind of slowly and imperceptibly disappearing from the public consciousness over the course of around 40 years…" Buterin said during a podcast appearance back in 2021. 

Fighting aging Buterin is, of course, far from being the only prominent executive who is advocating against aging.  There are several other tech executives and prominent figures known for their strong interest in anti‑aging or longevity research.

For instance, Bryan Johnson, founder of companies like Kernel and Braintree, famously runs a highly publicised anti‑aging program called "Project Blueprint." It involves an intense diet, supplements, and biomarkers. 

Billionaire Peter Thiel, who is also known as a prominent crypto investor,  has invested heavily in companies addressing aging and life extension. He has donated millions to longevity research via foundations like the Methuselah Foundation. 

OpenAI CEO Sam Altman has also been actively investing in longevity research. 

Ethereum is once again testing a major resistance level that could define its next big move. After a steady recovery from recent lows, ETH has approached the $3,700 zone, a price area that traders view as the dividing line between bullish continuation and potential reversal.

According to market analyst Ali Martinez, XRP whales have offloaded roughly 900,000 coins in just five days, a move that may signal shifting short-term sentiment.

On-chain data indicates these large holders could be taking profits from recent price gains or repositioning ahead of expected market volatility.

Source: Ali Martinez
Notably, whale behavior typically cycles between accumulation and profit-taking, with large holders shifting assets for treasury management, portfolio rebalancing, or strategic selling.

Therefore, the recent offloading of 900,000 XRP by major holders signals rising caution among whales. Though not an outright bearish indicator, it adds a critical layer of uncertainty to XRP’s market structure.

Ripple’s RLUSD Stablecoin Surpasses $1 Billion Market Cap
Ripple’s U.S. dollar-backed stablecoin, RLUSD, recently surpassed $1 billion in market capitalization, marking a significant milestone in the company’s expanding role within the digital asset ecosystem, per CryptoQuant data.

Advertisement
 

Source: CryptoQuant
Additionally, CoinMarketCap data showed RLUSD’s circulating supply reaching 1.02 billion tokens, split across the Ethereum and XRP Ledger (XRPL) networks.

Notably, the dual-chain issuance highlights Ripple’s commitment to cross-network interoperability and institutional-grade liquidity, reinforcing its mission to unite traditional finance with blockchain innovation.

Deploying RLUSD on Ethereum unlocks access to the world’s most active DeFi ecosystem, while XRPL integration delivers ultra-fast, low-cost transactions, a strategic edge for global payments and remittances.

Therefore, RLUSD’s rapid growth could become a key driver of Ripple’s ecosystem expansion. Its dual-chain interoperability across Ethereum and XRPL gives it a clear edge over single-chain stablecoins, enabling smoother liquidity flows across DEXs, payment platforms, and cross-border settlement networks.

Meanwhile, Ripple recently secured $500 million in a strategic round led by Fortress Investment Group, propelling its valuation to an impressive $40 billion.

Key takeaways:

Solana’s strong onchain metrics and DApps revenue dominance hint at long-term strength despite recent selling pressure from major holders.

Solana ETF inflows and diversified onchain activity support SOL, yet macro risks in AI and trade remain key obstacles to a $250 recovery.

Solana’s native token, SOL (SOL), fell 6% after flirting with $172 on Monday. The drop largely mirrored a pullback in the Nasdaq Index, which came under pressure after CoreWeave (CRVW US) cut its cloud services revenue forecast and reports surfaced that China plans to ban the US military from accessing its rare-earth minerals. Is there any chance for SOL to reclaim the $250 level in the near term?

SOL/USD (blue) vs. Altcoin market cap (red). Source: TradingView / CointelegraphSOL has underperformed the altcoin market by 7% over the past two weeks, with no clear catalyst for the decline. In fact, the backdrop has been rather encouraging, marked by the debut of a Solana spot exchange-traded fund (ETF) in the US and a notable uptick in Solana’s onchain activity.

Blockchains ranked by 30-day fees. Source: NansenNetwork activity on Solana has surged over the past 30 days, with active addresses increasing by 10% and transactions rising by 8%. By comparison, Ethereum saw 5% fewer active addresses and a 26% drop in transactions during the same period. Hyperliquid, a rising competitor in the decentralized exchange (DEX) space, also experienced a 28% decline in onchain activity.

30-day DApp revenue by chain, USD. Source: DefiLlamaSolana continues to dominate in decentralized applications (DApps) revenue. No other network comes close, giving Solana a sustainable competitive edge. These DApps reward users by sharing part of their earnings as yield, a mechanism that helps the network attract more deposits and reinforce its position.

Solana’s growth shows stronger diversification across multiple sectorsThe total value locked (TVL) on Solana currently stands at $12 billion, widening the gap with BNB Chain, which holds $8 billion. Over the past 30 days, several projects have posted strong gains, including a 35% increase in Securitize (Real World Assets), a 31% rise in Solstice USX (Basis Trading), and a 10% uptick in deposits on Meteora (Liquidity Pools). This data suggests that Solana’s growth is becoming more diversified and less reliant on a single sector.

Weekly DEX volumes by chain, USD. Source: DefiLlamaMemecoin launches and trading activity were once the main forces driving Solana’s user growth and network fees, but that momentum faded by March. While the token has since recovered from its 2025 low of $95, traders remain cautious about its near-term upside.

Since their debut in US markets on Oct. 28, spot Solana ETFs have attracted $343 million in net inflows. Meanwhile, the REX-Osprey SOL + Staking ETF has accumulated an additional $286 million in assets. However, the overall positive effect of these instruments has been partly offset by outflows from companies reducing their SOL holdings.

Solana treasury holdings, SOL. Source: CoinGeckoThe sale of 439,621 SOL by Galaxy Digital Holdings (GLXY) has raised concerns about the sustainability of Solana’s corporate reserve strategy. Forward Industries (FORD) holds the largest position, with 6.82 million SOL, a figure that has remained steady over the past 30 days, according to CoinGecko data.

The odds still favor SOL outperforming the broader altcoin market, supported by Solana’s steady growth in onchain activity and its dominance in DApps revenue. However, the path toward $250 will likely depend on a decline in risks surrounding the artificial intelligence sector and a cooling of geopolitical tensions tied to the ongoing global trade war.

This article is for general information purposes and is not intended to be and should not be taken as legal or investment advice. The views, thoughts, and opinions expressed here are the author’s alone and do not necessarily reflect or represent the views and opinions of Cointelegraph.

Key takeaways:

Solana’s strong onchain metrics and DApps revenue dominance hint at long-term strength despite recent selling pressure from major holders.

Solana ETF inflows and diversified onchain activity support SOL, yet macro risks in AI and trade remain key obstacles to a $250 recovery.

Solana’s native token, SOL (SOL), fell 6% after flirting with $172 on Monday. The drop largely mirrored a pullback in the Nasdaq Index, which came under pressure after CoreWeave (CRVW US) cut its cloud services revenue forecast and reports surfaced that China plans to ban the US military from accessing its rare-earth minerals. Is there any chance for SOL to reclaim the $250 level in the near term?

SOL/USD (blue) vs. Altcoin market cap (red). Source: TradingView / CointelegraphSOL has underperformed the altcoin market by 7% over the past two weeks, with no clear catalyst for the decline. In fact, the backdrop has been rather encouraging, marked by the debut of a Solana spot exchange-traded fund (ETF) in the US and a notable uptick in Solana’s onchain activity.

Blockchains ranked by 30-day fees. Source: NansenNetwork activity on Solana has surged over the past 30 days, with active addresses increasing by 10% and transactions rising by 8%. By comparison, Ethereum saw 5% fewer active addresses and a 26% drop in transactions during the same period. Hyperliquid, a rising competitor in the decentralized exchange (DEX) space, also experienced a 28% decline in onchain activity.

30-day DApp revenue by chain, USD. Source: DefiLlamaSolana continues to dominate in decentralized applications (DApps) revenue. No other network comes close, giving Solana a sustainable competitive edge. These DApps reward users by sharing part of their earnings as yield, a mechanism that helps the network attract more deposits and reinforce its position.

Solana’s growth shows stronger diversification across multiple sectorsThe total value locked (TVL) on Solana currently stands at $12 billion, widening the gap with BNB Chain, which holds $8 billion. Over the past 30 days, several projects have posted strong gains, including a 35% increase in Securitize (Real World Assets), a 31% rise in Solstice USX (Basis Trading), and a 10% uptick in deposits on Meteora (Liquidity Pools). This data suggests that Solana’s growth is becoming more diversified and less reliant on a single sector.

Weekly DEX volumes by chain, USD. Source: DefiLlamaMemecoin launches and trading activity were once the main forces driving Solana’s user growth and network fees, but that momentum faded by March. While the token has since recovered from its 2025 low of $95, traders remain cautious about its near-term upside.

Since their debut in US markets on Oct. 28, spot Solana ETFs have attracted $343 million in net inflows. Meanwhile, the REX-Osprey SOL + Staking ETF has accumulated an additional $286 million in assets. However, the overall positive effect of these instruments has been partly offset by outflows from companies reducing their SOL holdings.

Solana treasury holdings, SOL. Source: CoinGeckoThe sale of 439,621 SOL by Galaxy Digital Holdings (GLXY) has raised concerns about the sustainability of Solana’s corporate reserve strategy. Forward Industries (FORD) holds the largest position, with 6.82 million SOL, a figure that has remained steady over the past 30 days, according to CoinGecko data.

The odds still favor SOL outperforming the broader altcoin market, supported by Solana’s steady growth in onchain activity and its dominance in DApps revenue. However, the path toward $250 will likely depend on a decline in risks surrounding the artificial intelligence sector and a cooling of geopolitical tensions tied to the ongoing global trade war.

This article is for general information purposes and is not intended to be and should not be taken as legal or investment advice. The views, thoughts, and opinions expressed here are the author’s alone and do not necessarily reflect or represent the views and opinions of Cointelegraph.

Trusted Editorial content, reviewed by leading industry experts and seasoned editors. Ad Disclosure

As the market recovers, Bitcoin appears to be displaying renewed bullish strength following several weeks of heightened volatility that caused its price to fall below the $100,000 mark. During this downward trend, many new BTC whales or large holders experienced notable losses, triggering a massive wave of capitulation among these key investors.

New Bitcoin Whales Break Under Pressure
One of Bitcoin’s most influential investor groups: newly formed whale addresses have taken a hit in a market where sentiment is still ambiguous. Bitcoin’s volatile swing in the past few weeks has now sent these key investors’ positions into severe losses, as the price drops below their entry levels. 

MorenoDV, a market expert and author, shared this crucial development in a quick-take post on the CryptoQuant platform after examining the Bitcoin Realized Profits by Whales metric. Specifically, this vital metric helps to determine whether these investors are capitulating (realized losses) or are distributing at a profit (realized gains).

BTC new whales are realizing losses | Source: Chart from CryptoQuant on X
Following the investigation, the expert found that Bitcoin is currently experiencing one of the most aggressive capitulations of the year by new whale entrants. Such a development indicates that the cohort is heavily exiting their positions under pressure, a sign of fear or a dramatic shift in attitude.

Data shows that the new whale investors have realized more than $1.3 billion in losses over the past 6 days, signifying one of 2025’s most aggressive selling campaigns. With significant amounts of BTC being sold at a loss, speculations are whether this is an early signal of deeper weakness in the crypto asset’s short-term price outlook.

What’s Driving The Heightened Selling Pressure Of The Cohort?
According to the expert, sustained losses of this magnitude are indicative of forced selling or panic-driven exits. Meanwhile, this is often caused by the loss of aversion of late entrants or the unwinding of leveraged positions. Given the current bullish state and resilience of the BTC market, MorenoDV stated that this event is a remarkable one.

Despite witnessing one of the biggest capitulation waves among new whales this year, the price of Bitcoin has held between the $100,000 and $105,000 support range so far. In the past, such periods of realized loss concentration have persistently triggered volatility spikes. These spikes either mark local bottoms or lead to extended deleveraging, depending on the market liquidity conditions.

Specifically, the data suggests pain among short-term large holders. However, the capability of the market to absorb this pressure without breaking down may point to underlying demand or accumulation by stronger hands. In the meantime, the expert declares that the upcoming days will help gauge whether this was the last shakeout or a sign of far deeper structural stress.

Providing more data on the trend, CryptoQuant highlighted that Bitcoin has been below the average cost basis of new whales positioned at the $110,800 level since October 28, triggering significant realized losses. The chart displays realized losses of $286.4 million, $90.7 million, $107.5 million, $515.1 million, and $5.1 million on November 4, 5, 6, 7, and 8, respectively.

BTC trading at $104,783 on the 1D chart | Source: BTCUSDT on Tradingview.com
Featured image from Pixabay, chart from Tradingview.com

Editorial Process for bitcoinist is centered on delivering thoroughly researched, accurate, and unbiased content. We uphold strict sourcing standards, and each page undergoes diligent review by our team of top technology experts and seasoned editors. This process ensures the integrity, relevance, and value of our content for our readers.

TL;DR

Injective launches its native EVM mainnet, enabling EVM and WASM operations in a unified environment with assets, liquidity, and over 30 ready-to-use dApps.
The platform integrates an institutional liquidity module (CLOB) and the MultiVM Token Standard, ensuring immediate liquidity, token interoperability, and operational security.
Developers can use standard Ethereum tools and plug-and-play financial modules.

Injective launches its native EVM mainnet, marking a key advance in on-chain finance infrastructure. The network allows developers and users to operate on both Ethereum Virtual Machine (EVM) and WebAssembly (WASM) in a unified environment with shared assets, liquidity, and Web3 modules. The platform already supports more than 30 dApps and infrastructure ready for advanced financial application development.

Injective’s testnet processed over 5 billion on-chain transactions across 300,000 unique wallets, validating the network’s capacity to handle high transaction volumes. The native mainnet reduces blockchain frictions: it eliminates platform incompatibilities, accelerates transaction speeds, and lowers fees. In addition, it unifies assets within a single ecosystem.

Key Advantages for Developers
The launch provides a MultiVM environment where EVM and WASM coexist without compromising performance or functionality. Every dApp and token benefits from a shared liquidity layer, enabling smooth and efficient interactions across the ecosystem. Developers can use standard Ethereum development tools such as Hardhat and Foundry without modifications, integrating plug-and-play financial modules that significantly reduce development time.

Injective includes an institutional liquidity module (CLOB), allowing new applications to access high-quality liquidity from day one, eliminating the cold-start problem that limits many platforms. This also enables applications to quickly tokenize and issue real-world assets (RWA), expanding investment and risk management options.

Injective Aims to Create a Circular Process: More dApps, More Developers, More Users, More Liquidity
The MultiVM Token Standard (MTS) ensures that every token has a consistent representation across all dApps, eliminating manual bridges and duplicate token versions. Complex operations execute atomically, protecting user funds and data integrity.

The platform already offers lending markets, tokenized assets, pre-IPO exposure, advanced derivatives, and perpetual futures, along with institutional-grade infrastructure and custody services.

Injective seeks to generate a virtuous cycle: more dApps attract more developers and users, increasing liquidity and activity, which in turn draws new applications and business opportunities.

Injective’s latest upgrade transforms its blockchain into a dual-execution environment, where Ethereum-based applications can run directly on-chain alongside its existing Cosmos-native dApps.

Summary

Injective launches native EVM, enabling Ethereum apps to run alongside Cosmos-native dApps.
Over 30 dApps and infrastructure providers go live on Injective’s upgraded mainnet.

In a statement dated Nov. 11, layer-1 blockchain Injective announced the successful deployment of its native Ethereum Virtual Machine, a core protocol upgrade that fundamentally expands its execution capabilities.

This architectural shift moves beyond simple compatibility, embedding an EVM directly into its state machine and enabling the chain to process Ethereum-native smart contracts and Cosmos-based WebAssembly applications in a single, synchronized environment. The rollout is accompanied by over 30 dApps and infrastructure providers going live on the network from day one, according to the statement.

“This launch represents Injective’s MultiVM vision coming to life. Developers now choose between WebAssembly (WASM) and Ethereum Virtual Machine (EVM) execution, with Solana VM support on the roadmap. This flexibility combined with Injective’s advanced financial modules creates unprecedented opportunities for innovation,” the Injective team said.

Injective’s EVM upgrade tackles blockchain frictions
Injective’s architectural shift is designed to tackle several persistent issues in decentralized finance. The platform addresses industry fragmentation by enabling applications running on different virtual machines to interact seamlessly on a shared liquidity layer. This eliminates the need for complex bridging operations that have often introduced risk and friction for users moving assets between ecosystems.

For developers, the environment offers familiar Ethereum tooling like Hardhat and Foundry, significantly lowering the barrier to entry for teams already skilled in Solidity. This is coupled with what Injective calls its “plug-and-play” financial modules, which provide pre-built components for complex functions like derivatives trading.

At the same time, the network’s shared central limit order book module provides new applications with immediate access to deep, MEV-resistant liquidity from their inception, aiming to solve the notorious “cold start” problem that has stifled many nascent DeFi projects.

Injective’s universal MultiVM Token Standard (MTS) further strengthens the ecosystem by providing a consistent token representation across all dApps. Users no longer face confusion from duplicate token versions or manual bridging, and complex operations execute atomically, preserving both funds and data integrity.

For end users, the practical outcome is access to a broader suite of financial applications without leaving the Injective chain. The statement points to new capabilities, including lending and borrowing markets, tokenized real-world assets, and advanced derivatives, all operating with the network’s characteristic sub-second finality and transaction fees that amount to a fraction of a cent.

Shiba Inu (CRYPTO: SHIB) has been stuck inside tightening price action for months, and the next weekly close will likely determine its direction. Price Compresses Between Multi-Year Trendline And Long-Term Support SHIB Weekly Price Action (Source: TradingView) On the weekly chart, SHIB trades near $0.00000975 to $0.00000980, staying pinned below a descending trendline that has rejected every breakout since October 2021.

Featured

28M CHF Secured by Adam Back and FUTURE for Bitcoin Treasury Project

Tl;DR FUTURE obtuvo 28 millones de francos suizos en nueva financiación. Entre sus directivos se encuentran Adam Back y Richard Byworth. La empresa tiene previsto

Companies

New Smart Contract Language for Bitcoin Unveiled: Blockstream Presents Simplicity

TL;DR: Blockstream launched Simplicity, a Bitcoin-native smart contract language on Liquid sidechain, enabling secure vaults, multi-party controls, and threshold signatures. Its “security-first” design eliminates recursion/infinite

Companies

Blockstream Introduces New Self-Custodial Bitcoin Wallet

TL;DR Enhanced Self-Custody: Blockstream unveils a revamped Bitcoin wallet built on the Blockstream Green platform, enabling users to buy, store, and manage Bitcoin. Robust Security:

Companies

Blockstream to Launch Bitcoin Investment Funds—What to Expect

TL;DR Blockstream is launching three Bitcoin-backed investment funds after securing a multimillion-dollar capital injection, with an official launch set for April 1.  Two funds will

Bitcoin News

Bitcoin (BTC) Market Cap Can Hit $200 Trillion in 9 Years

Adam Back, the co-founder of a company focusing on storing and transferring Bitcoin and other digital assets, Blockstream, believes Bitcoin (BTC) can surge to $10

CryptoCurrency News

Blockstream CEO Adam Back Says CBDCs are Worse Than Bank Accounts

Central Bank Digital Currencies (CBDCs) are becoming more and more common as several countries continue to explore the concept. Many experts believe that these assets

The Investment Committee give you their top stocks to watch for the second half.

Investors might want to bet on Advanced Energy Industries (AEIS - Free Report) , as earnings estimates for this company have been showing solid improvement lately. The stock has already gained solid short-term price momentum, and this trend might continue with its still improving earnings outlook.

The rising trend in estimate revisions, which is a result of growing analyst optimism on the earnings prospects of this maker of power-conversion products, should get reflected in its stock price. After all, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements. Our stock rating tool -- the Zacks Rank -- is principally built on this insight.

The five-grade Zacks Rank system, which ranges from a Zacks Rank #1 (Strong Buy) to a Zacks Rank #5 (Strong Sell), has an impressive externally-audited track record of outperformance, with Zacks #1 Ranked stocks generating an average annual return of +25% since 2008.

For Advanced Energy Industries, there has been strong agreement among the covering analysts in raising earnings estimates, which has helped push consensus estimates considerably higher for the next quarter and full year.

The chart below shows the evolution of forward 12-month Zacks Consensus EPS estimate:

12 Month EPS

Current-Quarter Estimate RevisionsThe company is expected to earn $1.71 per share for the current quarter, which represents a year-over-year change of +31.5%.

Over the last 30 days, the Zacks Consensus Estimate for Advanced Energy has increased 20.59% because two estimates have moved higher compared to no negative revisions.

Current-Year Estimate RevisionsFor the full year, the company is expected to earn $6.13 per share, representing a year-over-year change of +65.2%.

In terms of estimate revisions, the trend for the current year also appears quite encouraging for Advanced Energy. Over the past month, four estimates have moved higher compared to no negative revisions, helping the consensus estimate increase 8.08%.

Favorable Zacks RankThe promising estimate revisions have helped Advanced Energy earn a Zacks Rank #1 (Strong Buy). The Zacks Rank is a tried-and-tested rating tool that helps investors effectively harness the power of earnings estimate revisions and make the right investment decision.

You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.

Our research shows that stocks with Zacks Rank #1 (Strong Buy) and 2 (Buy) significantly outperform the S&P 500.

Bottom LineWhile strong estimate revisions for Advanced Energy have attracted decent investments and pushed the stock 20.4% higher over the past four weeks, further upside may still be left in the stock. So, you may consider adding it to your portfolio right away.

Investors might want to bet on Palantir Technologies Inc. (PLTR - Free Report) , as earnings estimates for this company have been showing solid improvement lately. The stock has already gained solid short-term price momentum, and this trend might continue with its still improving earnings outlook.

The rising trend in estimate revisions, which is a result of growing analyst optimism on the earnings prospects of this company, should get reflected in its stock price. After all, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements. Our stock rating tool -- the Zacks Rank -- has this insight at its core.

The five-grade Zacks Rank system, which ranges from a Zacks Rank #1 (Strong Buy) to a Zacks Rank #5 (Strong Sell), has an impressive externally-audited track record of outperformance, with Zacks #1 Ranked stocks generating an average annual return of +25% since 2008.

For Palantir Technologies Inc., there has been strong agreement among the covering analysts in raising earnings estimates, which has helped push consensus estimates considerably higher for the next quarter and full year.

The chart below shows the evolution of forward 12-month Zacks Consensus EPS estimate:

12 Month EPS

Current-Quarter Estimate RevisionsThe company is expected to earn $0.23 per share for the current quarter, which represents a year-over-year change of +64.3%.

Over the last 30 days, the Zacks Consensus Estimate for Palantir Technologies has increased 27.53% because seven estimates have moved higher compared to no negative revisions.

Current-Year Estimate RevisionsFor the full year, the earnings estimate of $0.73 per share represents a change of +78.1% from the year-ago number.

There has been an encouraging trend in estimate revisions for the current year as well. Over the past month, nine estimates have moved up for Palantir Technologies versus no negative revisions. This has pushed the consensus estimate 15.14% higher.

Favorable Zacks RankThanks to promising estimate revisions, Palantir Technologies currently carries a Zacks Rank #2 (Buy). The Zacks Rank is a tried-and-tested rating tool that helps investors effectively harness the power of earnings estimate revisions and make the right investment decision.

You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.

Our research shows that stocks with Zacks Rank #1 (Strong Buy) and 2 (Buy) significantly outperform the S&P 500.

Bottom LineInvestors have been betting on Palantir Technologies because of its solid estimate revisions, as evident from the stock's 9.3% gain over the past four weeks. As its earnings growth prospects might push the stock higher, you may consider adding it to your portfolio right away.

Investors might want to bet on Cloudflare (NET - Free Report) , as earnings estimates for this company have been showing solid improvement lately. The stock has already gained solid short-term price momentum, and this trend might continue with its still improving earnings outlook.

Analysts' growing optimism on the earnings prospects of this web security and content delivery company is driving estimates higher, which should get reflected in its stock price. After all, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements. Our stock rating tool -- the Zacks Rank -- is principally built on this insight.

The five-grade Zacks Rank system, which ranges from a Zacks Rank #1 (Strong Buy) to a Zacks Rank #5 (Strong Sell), has an impressive externally-audited track record of outperformance, with Zacks #1 Ranked stocks generating an average annual return of +25% since 2008.

For Cloudflare, there has been strong agreement among the covering analysts in raising earnings estimates, which has helped push consensus estimates considerably higher for the next quarter and full year.

The chart below shows the evolution of forward 12-month Zacks Consensus EPS estimate:

12 Month EPS

Current-Quarter Estimate RevisionsThe earnings estimate of $0.27 per share for the current quarter represents a change of +42.1% from the number reported a year ago.

Over the last 30 days, the Zacks Consensus Estimate for Cloudflare has increased 157.14% because six estimates have moved higher compared to no negative revisions.

Current-Year Estimate RevisionsThe company is expected to earn $0.90 per share for the full year, which represents a change of +20.0% from the prior-year number.

In terms of estimate revisions, the trend for the current year also appears quite encouraging for Cloudflare. Over the past month, eight estimates have moved higher compared to no negative revisions, helping the consensus estimate increase 20.29%.

Favorable Zacks RankOur research shows that stocks with Zacks Rank #1 (Strong Buy) and 2 (Buy) significantly outperform the S&P 500.

Bottom LineCloudflare shares have added 8.1% over the past four weeks, suggesting that investors are betting on its impressive estimate revisions. So, you may consider adding it to your portfolio right away to benefit from its earnings growth prospects.

EnerSys (ENS - Free Report) could be a solid choice for investors given the company's remarkably improving earnings outlook. While the stock has been a strong performer lately, this trend might continue since analysts are still raising their earnings estimates for the company.

The rising trend in estimate revisions, which is a result of growing analyst optimism on the earnings prospects of this maker of industrial batteries, should get reflected in its stock price. After all, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements. This insight is at the core of our stock rating tool -- the Zacks Rank.

The five-grade Zacks Rank system, which ranges from a Zacks Rank #1 (Strong Buy) to a Zacks Rank #5 (Strong Sell), has an impressive externally-audited track record of outperformance, with Zacks #1 Ranked stocks generating an average annual return of +25% since 2008.

For EnerSys, there has been strong agreement among the covering analysts in raising earnings estimates, which has helped push consensus estimates considerably higher for the next quarter and full year.

The chart below shows the evolution of forward 12-month Zacks Consensus EPS estimate:

12 Month EPS

Current-Quarter Estimate RevisionsFor the current quarter, the company is expected to earn $2.73 per share, which is a change of -12.5% from the year-ago reported number.

Over the last 30 days, three estimates have moved higher for EnerSys compared to no negative revisions. As a result, the Zacks Consensus Estimate has increased 7.89%.

Current-Year Estimate RevisionsThe company is expected to earn $10.28 per share for the full year, which represents a change of +1.3% from the prior-year number.

The revisions trend for the current year also appears quite promising for EnerSys, with three estimates moving higher over the past month compared to no negative revisions. The consensus estimate has also received a boost over this time frame, increasing 5.33%.

Favorable Zacks RankThanks to promising estimate revisions, EnerSys currently carries a Zacks Rank #1 (Strong Buy). The Zacks Rank is a tried-and-tested rating tool that helps investors effectively harness the power of earnings estimate revisions and make the right investment decision.

You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.

Our research shows that stocks with Zacks Rank #1 (Strong Buy) and 2 (Buy) significantly outperform the S&P 500.

Bottom LineWhile strong estimate revisions for EnerSys have attracted decent investments and pushed the stock 16.7% higher over the past four weeks, further upside may still be left in the stock. So, you may consider adding it to your portfolio right away.

Hecla Mining (HL - Free Report) could be a solid choice for investors given the company's remarkably improving earnings outlook. While the stock has been a strong performer lately, this trend might continue since analysts are still raising their earnings estimates for the company.

The rising trend in estimate revisions, which is a result of growing analyst optimism on the earnings prospects of this precious metals company, should get reflected in its stock price. After all, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements. Our stock rating tool -- the Zacks Rank -- is principally built on this insight.

The five-grade Zacks Rank system, which ranges from a Zacks Rank #1 (Strong Buy) to a Zacks Rank #5 (Strong Sell), has an impressive externally-audited track record of outperformance, with Zacks #1 Ranked stocks generating an average annual return of +25% since 2008.

For Hecla Mining, there has been strong agreement among the covering analysts in raising earnings estimates, which has helped push consensus estimates considerably higher for the next quarter and full year.

The chart below shows the evolution of forward 12-month Zacks Consensus EPS estimate:

12 Month EPS

Current-Quarter Estimate RevisionsFor the current quarter, the company is expected to earn $0.13 per share, which is a change of +225.0% from the year-ago reported number.

The Zacks Consensus Estimate for Hecla Mining has increased 8.33% over the last 30 days, as one estimate has gone higher compared to no negative revisions.

Current-Year Estimate RevisionsFor the full year, the earnings estimate of $0.38 per share represents a change of +245.5% from the year-ago number.

In terms of estimate revisions, the trend for the current year also appears quite encouraging for Hecla Mining. Over the past month, two estimates have moved higher compared to no negative revisions, helping the consensus estimate increase 14.14%.

Favorable Zacks RankThe promising estimate revisions have helped Hecla Mining earn a Zacks Rank #2 (Buy). The Zacks Rank is a tried-and-tested rating tool that helps investors effectively harness the power of earnings estimate revisions and make the right investment decision.

You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.

Our research shows that stocks with Zacks Rank #1 (Strong Buy) and 2 (Buy) significantly outperform the S&P 500.

Bottom LineWhile strong estimate revisions for Hecla Mining have attracted decent investments and pushed the stock 11.4% higher over the past four weeks, further upside may still be left in the stock. So, you may consider adding it to your portfolio right away.

Key Takeaways Coach delivered 21% y/y revenue growth in 1Q26, led by strength across key regions.North America, China and Europe posted gains of 26%, 21% and 39%, reflecting Coach's global momentum.Coach's focus on innovation, storytelling and direct-to-consumer sales keeps it on track for its $10B goal.
Tapestry, Inc.’s (TPR - Free Report) Coach brand entered fiscal 2026 with exceptional momentum, underscoring its strength as a global leader in accessible luxury. In the fiscal first quarter, Coach delivered a 21% year-over-year revenue increase, driven by strong double-digit gains across all key regions.

North America advanced 26%, China rose 21% and Europe jumped 39% year over year, reflecting the brand’s broad-based appeal and growing international presence. The company also reported the addition of 1.7 million customers worldwide. This expanding base of younger shoppers highlights Coach’s success in building long-term brand equity through modern storytelling and inclusive design.

Handbag average unit retail rose in the mid-teens in the quarter, complemented by an increase in total handbag units sold despite reduced promotional activity. The strength of accessories, including charms and straps, reinforced Coach’s ability to personalize and elevate its offerings. In addition, footwear achieved double-digit gains, led by the sustained popularity of the High Line and Soho families, confirming the category’s strategic importance in driving diversification and customer acquisition.

Coach’s focus on creativity and innovation remained evident in its Spring 2026 runway presentation at New York Fashion Week, which received strong critical and consumer responses. Marketing investment represented roughly 11% of sales, up 43% from the prior year, demonstrating the brand’s continued commitment to meaningful storytelling and customer engagement.

The launch of Coach Coffee Shops at Jersey Gardens and Woodbury Commons offered immersive brand experiences for younger audiences, while the “One Coach” strategy, introducing full-price collection products into outlet locations, helped enhance accessibility and elevate price realization. With nearly 90% of sales generated through direct-to-consumer channels, Coach continues to capitalize on its agile model to connect with consumers where they shop most.

Tapestry expects Coach’s strong performance to continue. For the second quarter of fiscal 2026, the brand is projected to deliver low-double-digit revenue growth, equivalent to mid-20% growth on a two-year stacked basis, maintaining the momentum of the fiscal first quarter. For fiscal 2026 overall, Coach is expected to achieve low-double-digit revenue growth while sustaining its operating margin, even amid tariff headwinds and continued strategic investments.

With disciplined execution, an expanding global reach, and an emotional connection that continues to resonate with modern consumers, Coach remains central to Tapestry’s growth strategy and is firmly on track toward its long-term ambition of becoming a $10-billion global brand.

TPR’s Price Performance, Valuation & EstimatesShares of Tapestry have surged 62.4% year to date against the industry’s decline of 18.3%.

Image Source: Zacks Investment Research

From a valuation standpoint, TPR trades at a forward price-to-earnings ratio of 18.35X, slightly up from the industry’s average of 16.31X. It has a Value Score of B.

Image Source: Zacks Investment Research

The Zacks Consensus Estimate for Tapestry’s fiscal 2026 earnings implies year-over-year growth of 9.2%, whereas the same for fiscal 2027 indicates an uptick of 10.6%. Earnings estimates for fiscal 2026 and 2027 have been revised upward by 9 cents and 8 cents per share, respectively, in the past seven days.

Image Source: Zacks Investment Research

TPR currently carries a Zacks Rank #2 (Buy).

Other Key PicksSome other top-ranked stocks are Boot Barn Holdings, Inc. (BOOT - Free Report) , FIGS Inc. (FIGS - Free Report) and American Eagle Outfitters Inc. (AEO - Free Report) .

Boot Barn operates as a lifestyle retail chain devoted to western and work-related footwear, apparel and accessories. It currently flaunts a Zacks Rank of 1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

The Zacks Consensus Estimate for Boot Barn’s fiscal 2026 earnings and sales implies growth of 20.5% and 16.2%, respectively, from the year-ago actuals. Boot Barn delivered a trailing four-quarter average earnings surprise of 5.4%.

FIGS is a direct-to-consumer healthcare apparel and lifestyle brand. It has a Zacks Rank #1 at present.

The Zacks Consensus Estimate for FIGS’ current financial-year earnings and sales suggests growth of 300% and 5.4%, respectively, from the year-ago actuals. FIGS delivered a trailing four-quarter average earnings surprise of 87.5%.

American Eagle is a specialty retailer of casual apparel, accessories and footwear. It carries a Zacks Rank of 2 at present.

The Zacks Consensus Estimate for American Eagle's current fiscal-year earnings and sales suggests declines of 36.2% and 1.5%, respectively, from the year-ago actuals. AEO delivered a trailing four-quarter average earnings surprise of 30.3%.

TAG Immobilien AG (OTCPK:TAGOF) Q3 2025 Earnings Call November 11, 2025 4:00 AM EST

Company Participants

Martin Thiel - CFO, Co-CEO & Member of Management Board

Conference Call Participants

Marios Pastou - Sanford C. Bernstein & Co., LLC., Research Division
Andrew McCreath - Green Street Advisors, LLC
Thomas Neuhold - Kepler Cheuvreux, Research Division
Celine Huynh - Barclays Bank PLC, Research Division
Manuel Martin - ODDO BHF Corporate & Markets, Research Division
Kai Klose - Joh. Berenberg, Gossler & Co. KG, Research Division
Simon Stippig - Warburg Research GmbH

Presentation

Operator

Ladies and gentlemen, welcome to the TAG Immobilien Publication of Interim Statement Q3 2025 Conference Call. I am George, the Chorus Call operator. [Operator Instructions] The conference is being recorded. [Operator Instructions] The conference must not be recorded for publication or broadcast.

At this time, it's my pleasure to hand over to Mr. Martin Thiel, CFO. Please go ahead, sir.

Martin Thiel
CFO, Co-CEO & Member of Management Board

Yes. Many thanks, and good morning all, and a very warm welcome from our side. Many thanks for dialing in for our Q3 results. As always, let's start on Page #3 of the presentation, which shows a comprehensive overview about our results in the first 9 months and also gives a first outlook on the guidance for 2026.

Let's start with the operational development first in the first 9 months of 2025. FFO I in the first 9 months of 2025 came in at roughly EUR 136 million compared to the previous year, that's a 4% increase. And that's important to point out that this increase was mainly driven by a higher EBITDA contribution from our rental business in Germany and in Poland, which increased by 6% year-on-year.

Looking at the sales result in Poland, we had a result that was more or less on

Recommended For You